Your Messages Inbox
Your Article Summary
See Latest ArticlesAbbott Receives CE Mark for Company's Next-Generation XIENCE PRIME Drug Eluting Stent, Advancing Leadership Position
Abbott, 06/24/09
Abbott announced that it has received CE Mark for its next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. The company plans to launch XIENCE PRIME in a broad size matrix with lengths up to 38 mm in Europe in the third quarter.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Multaq Approved in the European Union for Patients with Atrial Fibrillation
Sanofi-aventis, 12/01/09
FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09
FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
BioMarin, 12/01/09
Article Search
Sponsor